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Background: It is a matter of debate whether metabolic syndrome (MS) improves cardiovascular risk prediction
beyond the risk associated with its individual components. The present study examined the association of MS score
with high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), resistin, adiponectin, and angiographic coronary
artery disease (CAD) severity according to the presence of DM. In addition, the predictive value of various clinical
and biochemical parameters were analyzed, including the MS score for angiographic CAD.
Methods: The study enrolled 363 consecutive patients (196 men, 62 ± 11 years of age) who underwent coronary
angiography for evaluation of chest pain. Blood samples were taken prior to elective coronary angiography. MS was
defined by the National Cholesterol Education Program criteria, with MS score defined as the numbers of MS
components. CAD was defined as > 50% luminal diameter stenosis of at least one major epicardial coronary artery.
CAD severity was assessed using the Gensini score.
Results: Of the 363 patients studied, 174 (48%) had CAD and 178 (49%) were diagnosed with MS. When the
patients were divided into 4 subgroups according to MS score (0–1, 2, 3, 4–5), IL-6 levels and the CAD severity as
assessed by the Gensini score increased as MS scores increased. In contrast, adiponectin levels decreased
significantly as MS scores increased. When subjects were divided into two groups according to the presence of DM,
the relationships between MS score and IL-6, adiponectin, and Gensini score were maintained only in patients
without DM. Age, smoking, DM, MS score, and adiponectin independently predicted angiographic CAD in the
whole population. However, age is the only predictor for angiographic CAD in patients with DM.
Conclusions: In the presence of DM, neither adipokines nor MS score predicted angiographic CAD. However, in
non-diabetic patients, IL-6 and adiponectin showed progressive changes according to MS score, and MS score was
an independent predictor of CAD in patients without DM.
Keywords: Metabolic syndrome, Adipokines, Coronary artery disease, Diabetes mellitus* Correspondence: cardioblues@yuhs.ac
1Cardiology Division, Department of Internal Medicine, Gangnam Severance
Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu,
Seoul 135-720, Korea
2Severance Institute for Vascular and Metabolic Research, Yonsei University
College of Medicine, Seoul, Korea
© 2013 Kim et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kim et al. Cardiovascular Diabetology 2013, 12:140 Page 2 of 7
http://www.cardiab.com/content/12/1/140Background
Metabolic syndrome (MS) is considered a clinical pre-
dictor of cardiovascular disease [1-3], and patients with
MS have a higher incidence of coronary artery disease
(CAD) than individuals without MS [4,5]. Visceral adipose
tissue plays a crucial role in the pathogenesis of MS [6].
Adipokines, which are bioactive derivatives produced by
the adipose tissue, may contribute to the pathogenesis
of cardiovascular disease in patients with MS. [7,8].
However, it is still debatable whether the CAD risk asso-
ciated with MS is above and beyond the risk associated
with its individual components [9,10]. Previous studies
have reported that the number of markers of MS, or the
MS score, is more useful than a binary definition of MS to
predict severity of CAD [11,12]. Moreover, the predictabil-
ity of MS for CAD arises primarily from high fasting blood
glucose [12] and the relationship between the MS score
and CAD severity is unclear in the presence of diabetes
mellitus (DM) [13].
To the best of the author’s knowledge, the effect of
DM on the relationship between MS score and levels of
inflammatory markers or adipokines has not been inves-
tigated. Therefore, the present study examined the asso-
ciation of MS score with high sensitivity C-reactive protein
(hs-CRP), interleukin-6 (IL-6), resistin, adiponectin, and
angiographic CAD severity according to the presence of
DM. In addition, this study analyzed the predictive value
of various clinical and biochemical parameters, includ-
ing MS score, for angiographic CAD.
Methods
Subjects
The study prospectively enrolled 363 consecutive patients
who underwent their first elective coronary angiography for
evaluation of chest pain from October 2007 to June 2008
at the Gangnam Severance Hospital, Yonsei University
College of Medicine, Seoul, Korea. Patients who had a
history of previous percutaneous coronary intervention
or coronary artery bypass graft were excluded. Other ex-
clusion criteria were acute myocardial infarction, appar-
ent infectious disease, chronic kidney disease, chronic
inflammatory disorders, and malignancy.
The study protocol was approved by the Institutional
Review Board of the Gangnam Severance Hospital, Yonsei
University College of Medicine, and a written informed
consent was obtained from each patient.
Definition of metabolic syndrome
The presence of MS was determined using the updated
2005 Third Adult Treatment Panel of the National Chol-
esterol Education Program criteria [14]. In the present
analysis, central obesity was considered to be present if
waist circumference was ≥ 90 cm in men and ≥ 80 cm in
women, using thresholds for the Asian population. Thosewho had any three or more of the five components were
classified as having MS. The MS score was defined as
the number of constituents of MS.
Biochemical assessment
Blood samples were taken in the early morning after
overnight fasting prior to elective coronary angiography.
Serum lipid profiles, fasting blood glucose, serum insulin,
and high sensitivity hs-CRP were measured in the hospital
laboratory. Insulin resistance was evaluated in non-diabetic
patients by the homeostatic model assessment as previously
described [15].
Blood samples for analysis of IL-6, resistin, and adiponectin
were collected through the vascular sheath prior to angi-
ography. Serum was separated and stored frozen at −80°C
for subsequent assay. Serum resistin and IL-6 were mea-
sured by enzyme-linked immunosorbent assay using com-
mercial kits (R&D Systems, Minneapolis, MN, USA). Serum
adiponectin levels were measured using a commercially
available radioimmunoassay (Linco Research, St. Charles,
MO, USA).
Angiographic assessment
Coronary angiography was performed by conventional
methods via the femoral artery. The angiographic char-
acteristics of all coronary lesions in the index coronary
angiogram were obtained by carefully reviewing the angio-
gram. CAD was defined as > 50% luminal diameter sten-
osis of at least one major epicardial coronary artery. CAD
severity was assessed using the Gensini scoring system as
previously described [16]. Grades of luminal stenosis
were determined by consensus opinion of two experienced
interventional cardiologists.
Statistical analyses
Continuous data are expressed as the mean ± S.D., and
categorical data are presented as numbers and percent-
ages. Differences in categorical variables were analyzed
using the chi-square test, and continuous variables were
analyzed using the Student’s t-test. Comparisons among
groups according to MS score were calculated with an
analysis of variance for continuous variables. Multivariate
logistic regression analysis was performed to determine
predictors of angiographic CAD. The base-2 logarithms
(log2) of the levels of hs-CRP, IL-6, resistin, and adiponectin
were used in logistic regression analysis to account for
skewed distribution [17,18]. Thus, odds ratios for these
parameters reflect the change in odds for an increase of
1 log2 (the equivalent of a doubling of the value) in the
measure. A 2-tailed p value < 0.05 was considered statis-
tically significant. All statistical analyses were performed
with PASW statistics version 18.0 (SPSS, Inc., Chicago,
IL, USA).
Table 1 Relative frequency of components of metabolic syndrome and clinical characteristics according to metabolic
syndrome score
Parameters MS scores Total(n = 363)
0,1 (n = 95) 2 (n = 90) 3 (n = 104) 4,5(n = 74)
High BP* 17 (18%) 57 (63%) 87 (84%) 68 (92%) 229 (63%)
High FBG† 4 (4%) 19 (21%) 44 (42%) 50 (67%) 117 (32%)
Low HDL-C‡ 17 (18%) 38 (42%) 70 (67%) 68 (92%) 193 (53%)
High TG§ 1 (1%) 13 (14%) 43 (41%) 60 (81%) 117 (32%)
Abdominal obesity║ 23 (24%) 53 (59%) 68 (65%) 68 (92%) 212 (58%)
Age (years) 61 ± 11 63 ± 11 63 ± 11 61 ± 10 62 ± 11
Male 53 (56%) 47 (52%) 57 (55%) 39 (53%) 196 (54%)
Smoking 14 (15%) 14 (16%) 14 (14%) 8 (11%) 50 (14%)
MS =metabolic syndrome; BP = blood pressure; FBG = fasting blood glucose; HDL-C = high-density lipoprotein cholesterol; TG = triglyceride.
*> 130/85 mmHg.
† ≥ 110 mg/dL.
‡For men < 40 mg/dL; for women < 50 mg/dL.
§≥ 150 mg/dL.
║For men, waist circumference > 90 cm; for women, waist circumference > 80 cm.
Table 2 Clinical and biochemical characteristics according






Age (years) 61.8 ± 11.5 62.2 ± 10.6 0.728
Male 100 (54%) 96 (54%) 0.981
BMI (kg/m2) 23.7 ± 2.8 26.0 ± 2.8 <0.001
Waist circumference (cm) 85.9 ± 8.6 92.9 ± 9.2 <0.001
Hip circumference (cm) 91.2 ± 8.2 95.2 ± 7.0 <0.001
Waist-hip ratio 0.94 ± 0.07 0.97 ± 0.11 0.064
Systolic BP (mmHg) 122.9 ± 17.4 127.2 ± 20.2 0.028
Diastolic BP (mmHg) 74.2 ± 10.4 75.7 ± 12.0 0.189
Smoking 28 (15%) 22 (12%) 0.443
Hypertension 74 (40%) 155 (87%) <0.001
Diabetes 17 (9%) 70 (39%) <0.001
Total cholesterol (mg/dL) 161.3 ± 35.2 153.3 ± 41.8 0.050
TG (mg/dL) 97.8 ± 37.3 158.5 ± 78.2 <0.001
HDL-C (mg/dL) 48.4 ± 11.9 39.6 ± 8.5 <0.001
LDL-C (mg/dL) 101.7 ± 34.4 97.6 ± 30.9 0.245
Lipoprotein(a) (mg/dL) 22.4 ± 28.5 18.9 ± 21.5 0.196
FBG (mg/dL) 96.1 ± 18.0 106.6 ± 25.6 <0.001
Serum insulin (μIU/mL) 5.5 ± 4.9 9.4 ± 13.3 <0.001
HOMA-IR* 1.4 ± 1.7 2.5 ± 3.5 <0.001
hs-CRP (mg/L) 5.4 ± 13.7 6.1 ± 17.3 0.716
IL-6 (pg/mL) 2.3 ± 3.7 3.0 ± 5.0 0.103
Resistin (ng/mL) 5.8 ± 3.8 7.1 ± 7.0 0.036
Adiponectin (μg/mL) 7.5 ± 5.7 5.8 ± 4.7 0.002
MS = metabolic syndrome; BMI = body mass index; BP = blood pressure;
TG = triglyceride; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol; FBG = fasting blood glucose; HOMA-IR = the
homeostatic model assessment of insulin resistance; hs-CRP = high sensitivity
C-reactive protein; IL-6 = interleukin-6.
*HOMA-IR was calculated only for non-diabetic patients (n = 276).
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A total of 363 patients (196 men, 62 ± 11 years of age)
were enrolled in this study. Of these 363 patients, 174
(48%) had CAD and 178 (49%) were diagnosed with MS.
The distribution of patients with an MS score of 0 to 5 is
presented in Table 1. In most groups, high blood pressure
was the most frequent abnormality, followed by increased
waist circumference, low high-density lipoprotein choles-
terol, high fasting blood glucose, and high triglycerides.
Demographic and biochemical characteristics of patients
with and without MS are presented in Table 2. Compared to
patients without MS, patients with MS had higher serum
resistin levels (7.1 ± 7.0 vs. 5.8 ± 3.8 ng/mL, p= 0.036) and
lower serum adiponectin levels (5.8 ± 4.7 vs. 7.5 ± 5.7 μg/mL,
p= 0.002). The levels of hs-CRP and IL-6 were not signifi-
cantly different between the groups with and without MS.
The homeostasis model assessment of insulin resistance
calculated for non-diabetic patients (n = 276) was higher
in patients with MS (2.5 ± 3.5 vs. 1.4 ± 1.7, p < 0.001).
The prevalence of angiographic CAD and multivessel
disease is higher in patients with MS (Table 3). More-
over, patients with MS had more severe CAD as assessed
by the Gensini score (20.7 ± 27.7 vs. 13.3 ± 20.4, p = 0.004).
However, clinical presentation of CAD was not signifi-
cantly different between the two groups.
When patients were divided into four subgroups
according to MS score, IL-6 levels and CAD severity
assessed by Gensini score tended to increase as MS
score increased (Table 4). Serum resistin tended to in-
crease with MS score, but this trend was not significant.
In contrast, adiponectin levels significantly decreased as
MS score increased. However, hs-CRP was not signifi-
cantly different among the four subgroups.
Table 3 Clinical presentation, angiographic diagnosis,
and severity of coronary artery disease according to






UA 35 (19%) 46 (26%) 0.072
Angiographic CAD 76 (41%) 98 (55%) 0.008
MVD 36 (20%) 56 (32%) 0.009
Gensini score 13.3 ± 20.4 20.7 ± 27.7 0.004
MS =metabolic syndrome; UA = unstable angina; CAD = coronary artery
disease; MVD =multi-vessel disease.
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according to the presence of DM, the relationships of
IL-6, adiponectin, and Gensini score with MS score
were maintained in patients without DM. In diabetic
patients, however, there was no significant relationship
between these parameters and MS score (Figure 1).
Various clinical and biochemical parameters including
traditional CAD risk factors, inflammatory markers,
adipokines, and MS score were analyzed for prediction
of angiographic CAD. When a multivariate logistic re-
gression analysis was performed, age, smoking, DM, MS
score, and adiponectin independently predicted angio-
graphic CAD in the entire population (Table 5). These
analyses were then performed in subgroups according
to presence of DM. Age, smoking, and MS score were
still independent predictors for angiographic CAD in
patients without DM. However, age is the only predictor
for angiographic CAD in patients with DM (Table 6).Discussion
MS is defined as the presence of any three or more
of five quantitatively identified markers. Although the
individual components of MS are related to one another,
patients with MS could be comprised of heterogeneous
subgroups [12]. Therefore, it has been a matter of debateTable 4 Inflammatory markers, adipokines, and severity of an
metabolic syndrome score
Parameters MS scores
0,1(n = 95) 2(n = 90)
hs-CRP (mg/L) 5.8 ± 14.3 5.0 ± 13.1
IL-6 (pg/mL) 2.0 ± 2.8 2.6 ± 4.4
Resistin (ng/mL) 5.7 ± 4.1 6.0 ± 3.4
Adiponectin (μg/mL) 8.4 ± 6.7 6.6 ± 4.2
Gensini score 9.4 ± 16.8 17.4 ± 22.9
MS =metabolic syndrome; hs-CRP = high sensitivity C-reactive protein; IL-6 = interlewhether MS improves cardiovascular risk prediction beyond
the risk associated with its individual components [9,10].
Some studies have reported that MS score is more useful
than the presence or absence of MS in predicting the
severity of CAD [11,12]. Moreover, it has been sug-
gested that MS predicts CAD based primarily on high
fasting blood glucose [12], and the relationship be-
tween the MS score and CAD severity is unclear in the
presence of DM [13].
The present study demonstrated that incremental changes
in angiographic CAD severity assessed by the Gensini
score were observed in accordance with MS score, and
MS score was an independent predictor for angiographic
CAD. However, in a diabetic subgroup, this association
was not observed, and MS score could not predict CAD.
These results are consistent with previous findings [13,19].
This study expands upon existing reports by demonstrat-
ing that MS scores are significantly related to IL-6 and
adiponectin levels in the non-diabetic subgroup, but not
in the diabetic subgroup. Regarding the prediction of
angiographic CAD, adiponectin showed marginal signifi-
cance only in the non-diabetic subgroup [20].
Although the pathophysiological mechanism by which
MS increases cardiovascular risk is still unclear [21], in-
sulin resistance and central obesity seem to be essential
components of MS [22,23]. Obesity as a predictor of
cardiovascular events is related to many cardiovascular
risk factors which are also components of MS [21,24]. It
has been shown that visceral adipose tissue is an active
endocrine organ which produces several bioactive de-
rivatives including proinflammatory and prothrombotic
adipokines, and protective adiponectin [25]. Visceral
fat accumulation followed by increased production of
proinflammatory adipokines and decreased production
of adiponectin is associated with individual compo-
nents of MS such as insulin resistance, hypertension,
and dyslipidemia [6]. Eventually, these abnormalities could
lead to atherosclerosis and cardiovascular events [26,27].
Some experts have suggested that increased cardiovas-
cular risk associated with MS primarily arises from thegiographic coronary artery disease according to
p
value3(n = 104) 4,5(n = 74)
5.2 ± 15.4 7.3 ± 19.8 0.827
2.4 ± 3.5 4.0 ± 6.5 0.024
6.6 ± 5.0 7.8 ± 9.1 0.077
6.2 ± 5.1 5.3 ± 4.2 0.001
18.9 ± 24.8 23.1 ± 31.3 0.002
ukin-6.
Figure 1 Relation of metabolic syndrome score with interleukin-6 (A), adiponectin (B), and Gensini score (C) according to the presence
of diabetes. Data are expressed as mean ± standard deviation. DM, diabetes mellitus; IL-6, interleukin-6. *p < 0.05 vs. metabolic syndrome (MS)
scores 4, 5 group; †p < 0.05 vs. MS score 3 group; ‡p < 0.001 vs. MS score 4, 5 group.
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Table 5 Multiple clinical and biochemical parameters as
determinants of angiographic coronary artery disease in
multivariate logistic regression analysis
Parameters Odds ratio (95% CI) p value
Age (per yr) 1.046 (1.018 – 1.074) 0.001
Smoking (yes) 4.155 (1.763 – 9.791) 0.001
Hypertension (yes) 0.661 (0.338 – 1.292) 0.661
Diabetes mellitus (yes) 2.290 (1.166 – 4.499) 0.016
Dyslipidemia (yes) 1.507 (0.746 – 3.045) 0.253
MS score (per 1 point) 1.452 (1.109 – 1.901) 0.007
hs-CRP (per doubling) 1.052 (0.862 – 1.284) 0.619
IL-6 (per doubling) 1.064 (0.781– 1.450) 0.695
Resistin (per doubling) 1.023 (0.669 – 1.565) 0.916
Adiponectin (per doubling) 0.683 (0.469 – 0.995) 0.047
MS = metabolic syndrome; hs-CRP = high sensitivity C-reactive protein;
IL-6 = interleukin-6; CI = confidence interval.
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definition of MS [28]. The results of the present study
also suggest that neither adipokines nor MS score have
an incremental value for the prediction of CAD in the
presence of DM. As DM is a very strong predictor of
cardiovascular disease, the five components of MS and
other non-traditional markers of cardiovascular disease
did not improve cardiovascular disease prediction be-
yond the contribution of DM [29].
The definition of MS excludes other factors related to
insulin resistance such as proinflammatory adipokines or
adiponectin. It is unclear whether inclusion of these
components would predict cardiovascular disease better
than the current components [28,30,31]. However, in the
non-diabetic subgroup, IL-6 and adiponectin changed
gradually according to MS score, and MS score predictedTable 6 Multivariate regression analysis for the prediction of
according to the presence of diabetes
Subjects without DM (n =
Parameters Odds ratio (95% CI)
Age (per yr) 1.043 (1.012 – 1.075)
Smoking (yes) 3.843 (1.514 – 9.753)
Hypertension (yes) 0.659 (0.311 – 1.397)
Dyslipidemia (yes) 1.210 (0.547 – 2.680)
MS score (per 1 point) 1.461 (1.078 – 1.981)
hs-CRP (per doubling) 1.066 (0.852 – 1.333)
IL-6 (per doubling) 1.087 (0.760 – 1.555)
Resistin (per doubling) 0.990 (0.610 – 1.609)
Adiponectin (per doubling) 0.646 (0.417 – 1.001)
MS =metabolic syndrome; hs-CRP = high sensitivity C-reactive protein; IL-6 = interleangiographic CAD. Therefore, MS score could be used as
a predictor of CAD in subjects without DM. The gradual
change of inflammatory markers or adipokines according
to MS score might be at least partly related with the use-
fulness of MS score in the prediction of CAD in non-
diabetic patients.
The present study has several limitations. Firstly,
the subjects in this study were patients who under-
went coronary angiography for clinically suspected CAD.
Therefore, the prevalence of DM (24%) or CAD (48%)
was quite high, and selection bias may affect the results.
Secondly, the severity of CAD was assessed by the
Gensini scoring system based on the degree of angio-
graphic luminal stenosis. Thus, lesion complexity or
plaque vulnerability could not be analyzed in the present
study. However, angiographic assessment of coronary
stenosis is a widely accepted and clinically useful
method for risk stratification in CAD patients. Lastly,
this was a cross-sectional study and therefore it was
not possible to determine causative relationships. In
addition, the effects of medications that could influ-
ence the levels of inflammatory cytokines and adipokines,
including anti-diabetic drugs, could not be fully analyzed
in this study. Therefore, we cannot rule out completely
the possibility that these medications might influence
the results in some cases.Conclusions
In the presence of DM, neither adipokines nor MS score
had incremental value for predicting angiographic CAD.
However, in non-diabetic patients, IL-6 and adiponectin
gradually changed according to the MS score, and MS
score predicted angiographic CAD. Therefore, MS
score could be a useful predictor of CAD in patients
without DM.angiographic coronary artery disease in subgroups
276) Subjects with DM (n = 87)
p value Odds ratio (95% CI) p value
0.006 1.079 (1.003 – 1.161) 0.041
0.005 9.428 (0.803 – 110.639) 0.074
0.277 0.442 (0.079 – 2.464) 0.352
0.638 5.860 (0.625 – 54.969) 0.122
0.015 1.598 (0.788 – 3.238) 0.193
0.577 0.929 (0.578 – 1.492) 0.759
0.648 1.063 (0.557 – 2.030) 0.853
0.969 1.195 (0.469 – 3.043) 0.709
0.051 0.985 (0.424 – 2.290) 0.972
ukin-6; DM = diabetes mellitus; CI = confidence interval.
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